Osnuvo
Teriparatide biosimilar developed by Avir Pharma. Reference product Forsteo (Forteo in the United States).
Brands by market: Osnuvo (Canada) · Commercial partner or holder: Avir Pharma · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCJan 2020approved
CDSCONot listed
EDENot listed
Approved or registered in 1 of 7 markets
Connections
About Osnuvo
Osnuvo is Avir Pharma's teriparatide, approved in Canada in January 2020. Avir is a Canadian specialty company and has not named the developer. It has no counterpart in other markets.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan
Not listed by PMDA.
HC
Canada · Osnuvo
Health CanadaApprovedBrand
Osnuvo
Holder or applicant
Avir Pharma INC.
Pathway
Biosimilar biologic drug (Notice of Compliance)
Approved
Jan 2020
Application or permission
DIN 02495589
Presentations
250 micrograms
Source
S022 (Health Canada) · checked Sep 2026
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- HCJan 2020Notice of Compliance, Health Canada
Sources
Planning teriparatide biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.